AstraZeneca's Imfinzi Sees Benefits In CASPIAN Study
Further details of Imfinzi’s benefits in small cell lung cancer, an aggressive and poorly treated tumor, from the interim analysis of the CASPIAN Phase III study, show statistically significant and clinically meaningful activity.
You may also be interested in...
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.